| 16.71 -0.17 (-1.01%) | 12-12 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 20.8  |
1-year : | 22.62 |
| Resists | First : | 17.81 |
Second : | 19.37 |
| Pivot price | 16.27 |
|||
| Supports | First : | 15.3 | Second : | 12.72 |
| MAs | MA(5) : | 16.55 |
MA(20) : | 16.43 |
| MA(100) : | 17.55 |
MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 69.6 |
D(3) : | 59 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 23 | Low : | 11.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ETON ] has closed below upper band by 24.4%. Bollinger Bands are 42.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 17.2 - 17.29 | 17.29 - 17.37 |
| Low: | 16.44 - 16.54 | 16.54 - 16.63 |
| Close: | 16.54 - 16.72 | 16.72 - 16.86 |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Thu, 11 Dec 2025
What is HC Wainwright's Estimate for ETON FY2025 Earnings? - MarketBeat
Wed, 10 Dec 2025
Q4 EPS Forecast for Eton Pharmaceuticals Lowered by Analyst - MarketBeat
Mon, 08 Dec 2025
Divisadero Street Capital Management LP Purchases New Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Thu, 04 Dec 2025
Implied Volatility Surging for Eton Pharmaceuticals Stock Options - TradingView — Track All Markets
Thu, 04 Dec 2025
Eton Pharmaceuticals Joins Piper Sandler Healthcare Conference - TipRanks
Mon, 24 Nov 2025
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 66.2 (%) |
| Shares Short | 2,780 (K) |
| Shares Short P.Month | 3,020 (K) |
| EPS | -0.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.86 |
| Profit Margin | -9.5 % |
| Operating Margin | -0.2 % |
| Return on Assets (ttm) | 1.2 % |
| Return on Equity (ttm) | -34.2 % |
| Qtrly Rev. Growth | 117.5 % |
| Gross Profit (p.s.) | 1.48 |
| Sales Per Share | 2.62 |
| EBITDA (p.s.) | 0.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 21 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -64.27 |
| PEG Ratio | 0 |
| Price to Book value | 19.43 |
| Price to Sales | 6.37 |
| Price to Cash Flow | 21.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|